Question 1

What is combined oxidative phosphorylation defect type 30?

Accepted Answer

Combined oxidative phosphorylation defect type 30 is a severe disorder affecting mitochondrial energy production, caused by mutations in the TRMT10C gene. This condition disrupts the normal function of mitochondria, interfering with the cell’s ability to produce energy and impacting multiple organ systems. It typically presents in early infancy with life-threatening issues including muscle weakness, respiratory failure, and metabolic disturbances. The condition is very rare, affecting fewer than 1 in 1,000,000 individuals, and arises due to an autosomal recessive inheritance pattern.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 30?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation defect type 30 is marked by a constellation of multisystem findings. Affected individuals almost universally exhibit hypotonia, failure to thrive, respiratory failure, and feeding difficulties, together with laboratory evidence of lactic acidosis such as increased lactate in the blood and CSF. Muscle biopsies typically reveal cytochrome C oxidase-negative fibers, decreased activity of mitochondrial complexes I and IV, and ragged-red fibers, underscoring a significant disturbance in muscle energy metabolism. In addition, many patients present with elevated liver enzymes, abnormal lactate:pyruvate ratios, and sensorineural hearing impairment, while other features such as gastroesophageal reflux, poor suck, left ventricular hypertrophy, and cerebral malformations like polymicrogyria are observed in a subset of cases. Not all individuals experience every feature, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 30?

Accepted Answer

Combined oxidative phosphorylation defect type 30 is caused by mutations in the TRMT10C gene, which plays a critical role in mitochondrial tRNA processing and, consequently, in the cell’s energy production pathways. Disruption of this gene impairs the normal function of mitochondrial complexes, leading to the biochemical and clinical manifestations seen in affected individuals. The condition follows an autosomal recessive pattern, meaning that an individual must inherit two mutated copies of TRMT10C, one from each parent, to be affected. This condition is more common when parents share a common ancestor, as this increases the likelihood that both carry the same rare pathogenic variant. Families are encouraged to seek genetic counseling to understand the implications for family planning and recurrence risk. Associated genes include TRMT10C.

Question 4

How is combined oxidative phosphorylation defect type 30 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 30 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 30?

Accepted Answer

combined oxidative phosphorylation defect type 30 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 30 diagnosed?

Accepted Answer

Diagnosis of combined oxidative phosphorylation defect type 30 is confirmed through molecular genetic testing that identifies pathogenic variants in the TRMT10C gene. In addition to genetic assays, a comprehensive clinical evaluation that considers the characteristic findings—such as hypotonia, respiratory failure, and biochemical markers like lactic acidosis—is essential. Because the symptoms can overlap with other mitochondrial and metabolic disorders, definitive diagnosis relies on the integration of molecular testing with clinical findings.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 30?

Accepted Answer

Currently, management of combined oxidative phosphorylation defect type 30 focuses on supportive care and symptom management, as there are no FDA-approved treatments available for this condition. Treatment plans are highly individualized and typically involve a multidisciplinary team that may include metabolic specialists, neurologists, and respiratory therapists. Supportive measures often include nutritional support to address failure to thrive, respiratory support to manage breathing difficulties, and careful monitoring of metabolic parameters such as lactate levels. Regular surveillance is an essential part of long-term care, ensuring that potential complications are identified and managed promptly. Patients and families are encouraged to discuss all treatment options with their healthcare team, and genetic counseling is recommended to support family planning decisions.

Question 8

What complications might arise from combined oxidative phosphorylation defect type 30?

Accepted Answer

Complications from combined oxidative phosphorylation defect type 30 can include severe muscle weakness, respiratory failure, and metabolic disturbances. Some patients may also experience elevated liver enzymes and sensorineural hearing impairment. Because the condition affects multiple organ systems, regular monitoring is essential to identify and manage potential complications early.

Question 9

How does combined oxidative phosphorylation defect type 30 affect daily life for patients and families?

Accepted Answer

Daily life for patients with combined oxidative phosphorylation defect type 30 can be challenging due to symptoms like hypotonia and feeding difficulties. Families often need to provide nutritional support and may require respiratory assistance for breathing issues. Regular medical appointments and therapies are important to manage the condition and ensure the best possible quality of life.

Question 10

What is the prognosis for individuals with combined oxidative phosphorylation defect type 30?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation defect type 30 varies widely based on symptom severity and the timeliness of supportive care. While many affected individuals may need intensive management early in life, advancements in care have improved outcomes. Families are encouraged to work closely with healthcare teams to navigate long-term management and support.

Question 11

What specialists should families consult for combined oxidative phosphorylation defect type 30?

Accepted Answer

Families dealing with combined oxidative phosphorylation defect type 30 should consult a multidisciplinary team of specialists. This may include metabolic specialists, neurologists, and respiratory therapists who can provide comprehensive care. Genetic counseling is also recommended to help families understand the condition and its implications for family planning.

Research Type	Count	% of Total
Laboratory research	58	58%

Kisho

combined oxidative phosphorylation defect type 30

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation defect type 30

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 30?

What are the symptoms of combined oxidative phosphorylation defect type 30?

What causes combined oxidative phosphorylation defect type 30?

How is combined oxidative phosphorylation defect type 30 inherited?

How rare is combined oxidative phosphorylation defect type 30?

How is combined oxidative phosphorylation defect type 30 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 30?

What complications might arise from combined oxidative phosphorylation defect type 30?

How does combined oxidative phosphorylation defect type 30 affect daily life for patients and families?

What is the prognosis for individuals with combined oxidative phosphorylation defect type 30?

What specialists should families consult for combined oxidative phosphorylation defect type 30?

Explore clinical features

Recent Publications